Monte Rosa Therapeutics Reports Promising Interim Phase 1 Data for MRT-8102 Targeting Elevated CVD Risk

BOSTON, Jan. 7, 2026 (GLOBE NEWSWIRE) - Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology firm specializing in molecular glue degrader (MGD) therapies, has released encouraging interim data from a Phase 1 clinical study of its investigational drug MRT-8102. This NEK7-directed MGD is designed to treat inflammatory diseases driven by NLRP3 inflammasome, IL-1, and IL-6, particularly in subjects at elevated risk for cardiovascular disease (CVD).

Key Findings from the MRT-8102 Study

The interim results demonstrate that after just four weeks of treatment with MRT-8102, C-reactive protein (CRP) levels were reduced by an impressive 85%. Notably, 94% of study participants achieved CRP levels below the 2 mg/L threshold, which is associated with decreased CVD risk. This clinical trial included comprehensive assessments through both single ascending dose (SAD) and multiple ascending dose (MAD) cohorts.

Safety and Efficacy Profile

The study outlined a favorable safety profile for MRT-8102, with adverse events primarily classified as mild to moderate and no indications of increased infection risk. The doses administered ranged from 5 mg to 400 mg, demonstrating sustained NEK7 degradation alongside significant reductions in inflammatory biomarkers. Among these, levels of IL-1β and IL-6 also showed promising declines in correlation with the treatment.

Anticipated Next Steps in Development

In light of these results, Monte Rosa plans to expand its ongoing GFORCE-1 study, which specifically targets subjects with elevated CVD risk, with anticipated results scheduled for H2 2026. Following this, the company is set to initiate the Phase 2 GFORCE-2 study of MRT-8102 in atherosclerotic cardiovascular disease (ASCVD) later this year. Additionally, further studies are being planned to explore other indications, including metabolic dysfunction-associated steatohepatitis (MASH), gout, and recurrent pericarditis, all of which are linked to NLRP3 pathway activation.

Corporate Milestones and Investor Engagement

Monte Rosa intends to share more detailed findings from the GFORCE-1 study in H2 2026. Furthermore, the company expects collaboration with Novartis to spark multiple Phase 2 studies of MRT-6160, aiming to address immune-mediated diseases. An investigation into a next-generation NEK7-directed MGD is also planned for submission later this year.

Investor Conference Call Information

Monte Rosa Therapeutics will host a conference call and webcast presentation today, January 7, 2026, at 8:00 a.m. ET. Interested parties can access the conference via the “Events & Presentations” section of Monte Rosa’s investor relations website at ir.monterosatx.com. An archived version of the webcast will be available for 30 days post-event.

About MRT-8102

MRT-8102 is an innovative investigational molecular glue degrader (MGD) that selectively targets NEK7. It is designed to mitigate inflammatory diseases tied to NLRP3, IL-1, and IL-6 dysregulation, representing a potential breakthrough in the treatment landscape for conditions associated with elevated cardiovascular risks.